Aldeyra Therapeutics (ALDX) Notes Payables (2013 - 2014)
Aldeyra Therapeutics' (ALDX) quarterly Notes Payables came in at $155097.0 in Q1 2014, up 82.47% on a QoQ basis from $85000.0 in Q4 2013.
Aldeyra Therapeutics (ALDX) Notes Payables (2013 - 2014) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 2 years of Notes Payables data on file, last reported at $155097.0 in Q1 2014.
- Quarterly Notes Payables changed N/A year-over-year to $155097.0 in Q1 2014, while the trailing twelve-month figure through Mar 2014 was $155097.0 (changed N/A YoY) and the FY2013 annual result came in at $85000.0, changed N/A from the prior year.
- Notes Payables climbed to $155097.0 in Q1 2014, from $85000.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $155097.0 in Q1 2014 to a low of $85000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - |
| 10 | Aldeyra Therapeutics | 94.16 Mn | 94.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 155,097.00 |
| Dec 31, 2013 | 85,000.00 |